A SYSTEMATIC REVIEW AND NETWORK META-ANALYSIS OF ANTI-DIABETES TREATMENTS FOR ADULTS WITH TYPE 2 DIABETES MELLITUS INADEQUATELY CONTROLLED ON INSULIN AND ORAL ANTI-DIABETES DRUGS

被引：0
|
作者：
Orme, M. [1 ]
Mukherjee, J. [2 ]
Sternhufvud, C. [3 ]
Smith, N. [4 ]
Fenici, P. [5 ]
机构：
[1] ICERA Consulting Ltd, Swindon, Wilts, England
[2] Bristol Myers Squibb Co, Wallingford, CT 06492 USA
[3] AstraZeneca, Malndal, Sweden
[4] Bristol Myers Squibb, Lawrenceville, NJ USA
[5] AstraZeneca, Melbourn, Herts, England
来源：
VALUE IN HEALTH | 2015年 / 18卷 / 03期
关键词：
D O I：
10.1016/j.jval.2015.03.328
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PDB21
引用
收藏
页码：A56 / A56
页数：1
相关论文
共 50 条
  • [1] A SYSTEMATIC REVIEW AND NETWORK META-ANALYSIS OF SECOND-LINE ANTI-DIABETES TREATMENTS FOR THOSE WITH TYPE 2 DIABETES MELLITUS INADEQUATELY CONTROLLED BY SULFONYLUREA MONOTHERAPY
    Orme, M. E.
    Fenici, P.
    Lomon, Duprat, I
    Wygant, G.
    Townsend, R.
    Roudaut, M.
    [J]. VALUE IN HEALTH, 2013, 16 (07) : A432 - A432
  • [2] A systematic review and mixed-treatment comparison of dapagliflozin with existing anti-diabetes treatments for those with type 2 diabetes mellitus inadequately controlled by sulfonylurea monotherapy
    Michelle Orme
    Peter Fenici
    Isabelle Duprat Lomon
    Gail Wygant
    Rebecca Townsend
    Marina Roudaut
    [J]. Diabetology & Metabolic Syndrome, 6
  • [3] A systematic review and mixed-treatment comparison of dapagliflozin with existing anti-diabetes treatments for those with type 2 diabetes mellitus inadequately controlled by sulfonylurea monotherapy
    Orme, Michelle
    Fenici, Peter
    Lomon, Isabelle Duprat
    Wygant, Gail
    Townsend, Rebecca
    Roudaut, Marina
    [J]. DIABETOLOGY & METABOLIC SYNDROME, 2014, 6
  • [4] Testing-and control among type 2 diabetes mellitus patients on oral anti-diabetes drugs
    Chapman, Richard H.
    Ferrufino, Cheryl P.
    Mac-Lean, John R.
    Krishnarajah, Shanthy
    [J]. DIABETES, 2008, 57 : A98 - A98
  • [5] Treatment failures in type 2 diabetes patients taking oral anti-diabetes drugs
    Chapman, Richard
    Ferrufino, Cheryl
    MaClean, John R.
    Krishnarajah, Girishanthy
    [J]. DIABETES, 2008, 57 : A348 - A349
  • [6] Dapagliflozin compared with other oral anti-diabetes treatments when added to metformin monotherapy: a systematic review and network meta-analysis
    Goring, S.
    Hawkins, N.
    Wygant, G.
    Roudaut, M.
    Townsend, R.
    Woody, I.
    Barnett, A. H.
    [J]. DIABETES OBESITY & METABOLISM, 2014, 16 (05): : 433 - 442
  • [7] An overview of the synthetic routes to essential oral anti-diabetes drugs
    Sagandira, Cloudius R.
    Khasipo, Agnes Z.
    Sagandira, Mellisa B.
    Watts, Paul
    [J]. TETRAHEDRON, 2021, 96
  • [8] A SYSTEMATIC LITERATURE REVIEW AND EVIDENCE SYNTHESIS OF ANTI-DIABETES TREATMENTS IN TYPE 2 DIABETES MELLITUS PATIENTS: INDIRECT COMPARISON OF EXENATIDE WITH METFORMIN plus SULPHONYLUREA
    King, D. T.
    Trautmann, M.
    Sabater, J.
    Pahor, A.
    Shaw, J. W.
    Grandy, S.
    Budd, D.
    Batson, S.
    [J]. VALUE IN HEALTH, 2014, 17 (03) : A238 - A238
  • [9] Willingness to pay for health improvements associated with anti-diabetes treatments for people with type 2 diabetes
    Jendle, J.
    Torffvit, O.
    Ridderstrale, M.
    Lammert, M.
    Ericsson, A.
    Bogelund, M.
    [J]. CURRENT MEDICAL RESEARCH AND OPINION, 2010, 26 (04) : 917 - 923
  • [10] Effects of anti-diabetes therapies on irisin secretion in type 2 diabetes patients
    Natalicchio, A.
    Marrano, N.
    Biondi, G.
    Le Grazie, G.
    Montedoro, A.
    Di Gioia, L.
    Guarini, F.
    Borrelli, A.
    Cignarelli, A.
    Perrini, S.
    Laviola, L.
    Giorgino, F.
    [J]. DIABETOLOGIA, 2021, 64 (SUPPL 1) : 243 - 243
12345